Date: Feb 7th, 2019
NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study
London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01.
The primary objective is to assess the change in PD-L1 expression in relation to immunotherapy in NSCLC and melanoma patients.
99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment.